The numbers are stark: more than 100,000 confirmed monkeypox cases across over 120 countries since January 2022, with over 200 deaths reported by September 2024. That data, from the European Centre for Disease Prevention and Control, underscores why the market for the Jynneos vaccine—one of the few tools effective against both monkeypox and smallpox—is drawing serious attention from governments, public health agencies, and investors alike.
The Business Research Company’s Jynneos Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035
The Jynneos vaccine market is drawing heightened interest as infectious disease threats like monkeypox and smallpox continue to challenge global health systems. Several forces are shaping its trajectory: public health initiatives, advances in vaccine technology, and a broader push to bolster readiness against emerging zoonotic diseases. Below, we break down the current market dynamics, growth catalysts, major developments, and regional trends.
Also worth a look: cplace AI Builder challenges enterprises to govern apps built in hours, not months and Vadzo Imaging validates 20MP camera for remote sites where bandwidth is scarce.
Steady Expansion of the Jynneos Market Through 2026
Historically, growth in the Jynneos market has been driven by global efforts to eradicate smallpox, responses to past monkeypox outbreaks, advancements in safer vaccinia-based vaccines, government preparedness programs, and public health vaccination campaigns. Moving forward, the market is expected to expand due to increasing risks from zoonotic diseases, growing national vaccine stockpiles, enhanced funding for biodefense, improvements in global disease surveillance, and wider adult immunization programs. Emerging trends forecasted to influence the market include greater emphasis on preventing infectious diseases, adoption of non-replicating vaccine platforms, expansion of government immunization initiatives, increased stockpiling of strategic vaccines, and heightened awareness about zoonotic infections.
Download a free sample of the jynneos market report:
https://thebusinessresearchcompany.com/sample_request?id=63212499&type=smp&name=Jynneos%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR
What Jynneos Is and How It Works
Jynneos is a vaccine designed to protect against both monkeypox and smallpox. It uses a modified vaccinia virus that does not replicate inside the body, yet still triggers an immune response capable of recognizing and fighting these viruses. That immune memory offers durable protection, reducing the chance of infection upon future exposure. Because it is non-replicating, Jynneos is considered a safer option than older smallpox vaccines, particularly for individuals with compromised immune systems.
Why the Market Is Growing: Monkeypox Cases Are the Driver
The rising number of monkeypox cases worldwide is a primary growth engine for the Jynneos market. Monkeypox, caused by the monkeypox virus from the orthopoxvirus family, has been spreading more rapidly due to increased global travel and closer human-wildlife contact, enabling transmission beyond isolated outbreaks. Jynneos has proven especially effective at protecting vulnerable populations. By September 2024, the European Centre for Disease Prevention and Control reported over 100,000 confirmed monkeypox cases across more than 120 countries since January 2022, along with more than 200 deaths. That surge is directly fueling demand for the vaccine.
View the full jynneos market report:
https://thebusinessresearchcompany.com/report/jynneos-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR
Combination Vaccines: A Growing Trend in Public Health Preparedness
A notable development within the Jynneos market is the push toward combination vaccines that protect against multiple diseases at once. These products reduce the number of injections needed, streamlining immunization campaigns. In August 2024, Bavarian Nordic A/S, a biotechnology firm based in Denmark, announced that Singapore’s Health Sciences Authority had approved JYNNEOS (MVA-BN) for preventing smallpox and pox in adults aged 18 and older who are at high risk. The non-replicating nature of JYNNEOS makes it a safer choice, especially for immunocompromised individuals, and reflects broader efforts to strengthen global readiness against emerging infectious threats.
Where the Market Stands: Regional Snapshot
In 2025, North America held the largest share of the Jynneos market, supported by robust healthcare infrastructure and government programs. Europe is projected to be the fastest-growing region through the forecast period. The market report covers key geographic areas including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, offering a comprehensive view of global trends and expansion.
New additions to our 2026 reports:
• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info
The Business Research Company – www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company.
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Why it matters: The Jynneos market is no longer a niche segment—it is becoming a central pillar of global biodefense strategy. With monkeypox cases showing no signs of disappearing and governments racing to stockpile vaccines, the demand trajectory points to sustained growth. For public health officials and investors alike, understanding this market is essential to anticipating how the world will prepare for the next zoonotic threat.
